Evaluation of YL201 in Patients with Advanced Solid Tumors: A Phase I Clinical Trial

The primary objective of the study is to evaluate the safety and efficacy of **YL201** in patients with **advanced solid tumors**. This is clinically relevant as advanced solid tumors often present significant treatment challenges, and new therapeutic options are needed to improve patient outcomes. The study aims to assess the potential of YL201 to provide clinical benefits in this patient population.

The clinical trial involves a total of **146 participants** diagnosed with **advanced solid tumors**. The study population includes both male and female subjects, with an age range spanning from young adults to older adults. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria. The health status of participants is generally characterized by the presence of advanced solid tumors, which is the primary medical condition under investigation.

The clinical trial is designed to evaluate the safety and efficacy of a new investigational product in patients with **advanced solid tumors**. This study is a Phase 1 trial, which is typically the first stage of testing in human subjects and focuses on assessing the safety profile of the investigational product. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from July 15, 2025, to June 30, 2028, allowing for comprehensive data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a thorough assessment of the participant's medical history and current health status. Following successful screening, participants will be randomly assigned to either the investigational product group or a control group. Throughout the trial, participants will attend regular follow-up visits, which are scheduled to monitor their health, assess the investigational product's effects, and ensure adherence to the study protocol. These visits will include physical examinations, laboratory tests, and other relevant assessments as deemed necessary by the study protocol.

The end-of-study visit marks the conclusion of the participant's involvement in the trial. During this visit, final evaluations will be conducted to gather comprehensive data on the investigational product's safety and efficacy. The expected length of participant involvement in the study is approximately three years, contingent upon individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions to the investigational product, non-compliance with study procedures, or withdrawal of consent by the participant.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The estimated recruitment start date is July 15, 2025, with an anticipated end date of June 30, 2028. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically focus on safety and dosage, with preliminary efficacy assessments often included. The trial will likely involve regular monitoring and data collection at predetermined intervals to evaluate the intervention's impact on the targeted medical condition. The analysis will be conducted using scientifically validated methods appropriate for early-phase clinical research. The trial's design will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.